Omeros secures FDA approval for YARTEMLEA, the first therapy for transplant-associated TA-TMA
FDA approves YARTEMLEA for TA-TMA. Find out how Omeros’ new drug could change transplant care for children and adults alike.
Pharma & Biotech
Pharma & Biotech
Can epigenome editing bypass gene size limits? Modalis’ LAMA1 data revives hope in congenital muscular dystrophy
Modalis unveils primate data showing safe LAMA1 gene activation for LAMA2-CMD. Find out what it means for CRISPR therapeutics and CMD patients.
Pharma & Biotech
QurAlis links QRL-101 to motor nerve excitability shift in ALS: Is target validation finally here?
QurAlis confirms target engagement of QRL-101 in ALS patients. Find out what this means for epilepsy trials and Kv7-targeted drug development.
Pharma & Biotech
Can Johnson & Johnson’s RIPTAC bet deliver the next wave of targeted oral cancer drugs?
Johnson & Johnson’s $3B Halda acquisition brings RIPTACs into focus. Find out what it means for prostate cancer therapy and precision oncology.
Pharma & Biotech
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.
Pharma & Biotech
Why Verastem Oncology’s KRAS G12C trial exit reveals a calculated pivot to next-generation lung cancer targets
Verastem exits its G12C lung cancer trial to prioritize VS-7375, a next-gen G12D inhibitor showing promise. Find out how this pivot could change KRAS therapy.
Pharma & Biotech
NeoImmuneTech takes over Endari’s U.S. rights from Emmaus: What this signals for the future of sickle cell treatment
NeoImmuneTech takes over U.S. rights for Endari from Emmaus Life Sciences. Find out what this deal reveals about the future of sickle cell treatment.
Pharma & Biotech
Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
Pharma & Biotech
Elanco wins USDA approval for Befrena, expanding mAb options in canine dermatitis
USDA approves Elanco’s Befrena for canine allergic dermatitis. Find out what it means for vets, pet owners, and the mAb dermatology race.
Pharma & Biotech
AstraZeneca, Daiichi Sankyo push Enhertu into early breast cancer with new FDA nod
AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results